Intrinsic Imaging Awarded International Phase III Trial for Novel Treatment of Non-Small Cell Lung Cancer Brain Metastases

Bolton, MA / San Antonio, TX — June 4, 2016 — Intrinsic Imaging, an FDA audited, ISO 9001, ISO 13485 and ISO 22301 certified imaging core lab, announced today that it has been awarded a global Phase III clinical trial designed to investigate the safety and efficacy of a novel approach to treat Non-Small Cell Lung Cancer Brain Metastases.

With its team of over 65 full-time board-certified, fellowship-trained radiologists, Intrinsic Imaging has extensive experience in providing services in support of Phase I-IV Clinical Trials and Class I, II and III Medical Device Trials.

Throughout this multi-year trial, which includes several thousand radiological reads, Intrinsic Imaging's oncology team of 10 full-time radiologists and 9 full-time neuroradiologists will bring their wealth of expertise and provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer and quality control, radiological review and data management.

"Intrinsic Imaging is proud to be selected to provide our expertise in assessing if this treatment will be effective to treat non-small cell lung cancer brain metastases," said Todd A. Joron, President & COO at Intrinsic Imaging. "The results of this Phase III study will determine if this novel approach compares favorably to the efficacy and safety of standard of care for this indication."